Aileen I. Fernandez, PhD, discusses the utility of fam-trastuzumab deruxtecan-nxki in HER2-low breast cancer.
Aileen I. Fernandez, PhD
Advertisement
Articles by Aileen I. Fernandez, PhD
Aileen I. Fernandez, PhD, discusses the need to refine immunohistochemistry testing in HER2-positive breast cancer.
Aileen I. Fernandez, PhD, discusses the results of a study examining low HER2 expression in breast cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Ris-Rez Extends Median OS to 18.5 Months vs Topotecan in Relapsed SCLC
2
Tam-Peli Reduces Risk of Death by 54% vs Topotecan in Relapsed SCLC
3
Iza-Bren Elicits 33% ORR, 6.9-Month PFS in Post-Osimertinib EGFR-Mutated NSCLC
4
Perioperative Atezolizumab Plus Chemotherapy Extends EFS in Resectable NSCLC
5